# Mesenchymal Stromal Cells for the Treatment of Patients With COVID-19.

> **NCT05433298** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Paulo Brofman**

## Conditions studied

- COVID-19 Pneumonia
- COVID-19

## Interventions

- **BIOLOGICAL:** Mesenchymal stem cell
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05433298
- **Lead sponsor:** Paulo Brofman
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-05-01
- **Primary completion:** 2022-11-26
- **Final completion:** 2023-03-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No patient could be included because there was a decrease in the number of patients with complications due to COVID-19. Also, a Brazilian government agency approved this clinical trial, and the project execution period ended in March 2023.
- **Last updated:** 2025-02-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05433298

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05433298, "Mesenchymal Stromal Cells for the Treatment of Patients With COVID-19.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05433298. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*